Overview: Deamidated Gliadin IgG TestIntroduction: The Deamidated Gliadin IgG Test detects IgG antibodies to deamidated gliadin to diagnose celiac disease, causing digestive issues or fatigue. Following 2023 AGA guidelines, it uses an immunoassay for high sensitivity, aiding in autoimmune screening. This test is critical for guiding diagnosis, dietary management, and improving outcomes in immunology, particularly for IgA-deficient patients with suspected celiac disease. It supports timely initiation of a gluten-free diet to alleviate symptoms.
Other Names: Gliadin IgG Assay, Deamidated Gliadin Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Gliadin IgG testing began in the 2000s with celiac research for IgA-deficient patients. Deamidated assays improved specificity in the 2010s, enhancing diagnostic accuracy.
Purpose: Diagnoses celiac disease, guides gluten-free diet, and monitors IgG antibodies in patients with digestive issues or fatigue, especially in IgA-deficient individuals.
Test Parameters: 1. Gliadin Deamidated IgG
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like digestive issues, fatigue, or weight loss, and list diet or medications.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document digestive issues, fatigue, or history of celiac disease. Include current diet (gluten exposure) and medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for dietary changes or further testing.
Procedural Considerations: Uses an immunoassay to detect deamidated gliadin IgG antibodies. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often used when IgA deficiency is suspected.
Factors Affecting Result Accuracy: Hemolysis or improper storage can affect results. A recent gluten-free diet may yield false negatives, requiring gluten challenge.
Clinical Significance: Positive IgG antibodies suggest celiac disease, prompting a gluten-free diet. Negative results may require further testing, especially in symptomatic patients.
Specialist Consultation: Consult a gastroenterologist for result interpretation and dietary management planning.
Additional Supporting Tests: Tissue transglutaminase IgG, small bowel biopsy, or HLA-DQ2/DQ8 testing to confirm celiac disease diagnosis.
Test Limitations: A recent gluten-free diet may cause false negatives. Results require clinical correlation and dietary history.
References: AGA Celiac Guidelines, 2023; Gastroenterology, Rubio-Tapia A, 2022.
